Introduction: Enzyme-induced corneal crosslinking (CXL) may be a promising and effective method to stiffen the cornea. However, there have been no reports on the effect of corneal CXL with enzyme in vivo. Objective: To evaluate the biomechanical efficacy after in vivo enzyme-induced corneal CXL in rabbits using noninvasive imaging. Methods: The eyes of 10 white New Zealand rabbits were unilaterally treated with CXL enzyme (transglutaminases [Tgases]). The contralateral eyes served as negative controls. In every rabbit, a 1 U/mL solution of Tgases was applied to the corneal surface. Corneal dynamic deformation by an air puff was measured using high-speed Scheimpflug imaging on day 14 after the procedure. Biomechanical parameters, central corneal thickness, and intraocular pressure were recorded and assessed. Then, corneal buttons were excised from euthanized animals for hematoxylin and eosin staining to evaluate changes in corneal collagen distribution and cell damage. Results: Some biomechanical parameters showed statistically significant changes after in vivo CXL. The deformation amplitude and maximum corneal velocity during the second applanations were significantly lower than those of the untreated control group. The second applanations were significantly increased compared to the control group. No changes were found in other parameters. The morphology of the corneal stroma was similar in CXL-treated and untreated corneas. No obvious cell apoptosis was observed. Conclusions: Corneal stiffness increased after in vivo CXL induced by Tgases. This CXL method may be useful for corneal ectasia.

1.
Ziaei
M
,
Barsam
A
,
Shamie
N
,
Vroman
D
,
Kim
T
,
Donnenfeld
ED
, et al.;
ASCRS Cornea Clinical Committee
.
Reshaping procedures for the surgical management of corneal ectasia
.
J Cataract Refract Surg
.
2015
Apr
;
41
(
4
):
842
72
.
[PubMed]
0886-3350
2.
Wollensak
G
,
Spoerl
E
,
Seiler
T
.
Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus
.
Am J Ophthalmol
.
2003
May
;
135
(
5
):
620
7
.
[PubMed]
0002-9394
3.
Greenstein
SA
,
Fry
KL
,
Hersh
PS
.
Corneal topography indices after corneal collagen crosslinking for keratoconus and corneal ectasia: one-year results
.
J Cataract Refract Surg
.
2011
Jul
;
37
(
7
):
1282
90
.
[PubMed]
0886-3350
4.
Webb
JN
,
Su
JP
,
Scarcelli
G
.
Mechanical outcome of accelerated corneal crosslinking evaluated by Brillouin microscopy
.
J Cataract Refract Surg
.
2017
Nov
;
43
(
11
):
1458
63
.
[PubMed]
0886-3350
5.
Hatami-Marbini
H
,
Jayaram
SM
.
UVA/riboflavin collagen crosslinking stiffening effects on anterior and posterior corneal flaps
.
Exp Eye Res
.
2018
Nov
;
176
:
53
8
.
[PubMed]
0014-4835
6.
Wollensak
G
,
Spoerl
E
,
Reber
F
,
Seiler
T
.
Keratocyte cytotoxicity of riboflavin/UVA-treatment in vitro
.
Eye (Lond)
.
2004
Jul
;
18
(
7
):
718
22
.
[PubMed]
0950-222X
7.
Greenstein
SA
,
Fry
KL
,
Bhatt
J
,
Hersh
PS
.
Natural history of corneal haze after collagen crosslinking for keratoconus and corneal ectasia: scheimpflug and biomicroscopic analysis
.
J Cataract Refract Surg
.
2010
Dec
;
36
(
12
):
2105
14
.
[PubMed]
0886-3350
8.
Mastropasqua
L
,
Nubile
M
,
Lanzini
M
,
Calienno
R
,
Mastropasqua
R
,
Agnifili
L
, et al.
Morphological modification of the cornea after standard and transepithelial corneal cross-linking as imaged by anterior segment optical coherence tomography and laser scanning in vivo confocal microscopy
.
Cornea
.
2013
Jun
;
32
(
6
):
855
61
.
[PubMed]
0277-3740
9.
Kopsachilis
N
,
Tsaousis
KT
,
Tsinopoulos
IT
,
Kruse
FE
,
Welge-Luessen
U
.
A novel mechanism of UV-A and riboflavin-mediated corneal cross-linking through induction of tissue transglutaminases
.
Cornea
.
2013
Jul
;
32
(
7
):
1034
9
.
[PubMed]
0277-3740
10.
Hassan
Z
,
Modis
L
 Jr
,
Szalai
E
,
Berta
A
,
Nemeth
G
.
Examination of ocular biomechanics with a new Scheimpflug technology after corneal refractive surgery
.
Cont Lens Anterior Eye
.
2014
Oct
;
37
(
5
):
337
41
.
[PubMed]
1367-0484
11.
Ali
NQ
,
Patel
DV
,
McGhee
CN
.
Biomechanical responses of healthy and keratoconic corneas measured using a noncontact scheimpflug-based tonometer
.
Invest Ophthalmol Vis Sci
.
2014
May
;
55
(
6
):
3651
9
.
[PubMed]
0146-0404
12.
Leung
CK
,
Ye
C
,
Weinreb
RN
.
An ultra-high-speed Scheimpflug camera for evaluation of corneal deformation response and its impact on IOP measurement
.
Invest Ophthalmol Vis Sci
.
2013
Apr
;
54
(
4
):
2885
92
.
[PubMed]
0146-0404
13.
Kymionis
GD
,
Grentzelos
MA
,
Kounis
GA
,
Portaliou
DM
,
Detorakis
ET
,
Magarakis
M
, et al.
Intraocular pressure measurements after corneal collagen crosslinking with riboflavin and ultraviolet A in eyes with keratoconus
.
J Cataract Refract Surg
.
2010
Oct
;
36
(
10
):
1724
7
.
[PubMed]
0886-3350
14.
Kasumovic
S
,
Mavija
M
,
Kasumovic
A
,
Lepara
O
, DuricColic B, Cabric E, et al. Intraocular Pressure Measurements Referring to the Corneal Thickness in Keratoconic Eyes After Corneal Crosslinking with Riboflavin and Ultraviolet A. Med Arch.
2015
DOI:
15.
GRIFFIN M
.
CASADIO R, BERGAMINI CM. Transglutaminases: nature’s biological glues
.
Biochem J
.
2002
;
•••
: 0264-6021
16.
Wollensak
G
,
Spoerl
E
,
Seiler
T
.
Stress-strain measurements of human and porcine corneas after riboflavin-ultraviolet-A-induced cross-linking
.
J Cataract Refract Surg
.
2003
Sep
;
29
(
9
):
1780
5
.
[PubMed]
0886-3350
17.
Wasilewski
D
,
Mello
GH
,
Moreira
H
.
Impact of collagen crosslinking on corneal sensitivity in keratoconus patients
.
Cornea
.
2013
Jul
;
32
(
7
):
899
902
.
[PubMed]
0277-3740
18.
Serna-Ojeda
JC
,
Santana-Cruz
O
,
Quiroz-Casian
N
,
González-Mendoza
E
,
Mercado-Orozco
JL
,
Navas
A
, et al.
Pain Management in Corneal Collagen Crosslinking for Keratoconus: A Comparative Case Series
.
J Ocul Pharmacol Ther
.
2019
Jul/Aug
;
35
(
6
):
325
30
.
[PubMed]
1080-7683
19.
Raychaudhuri
U
,
Millar
JC
,
Clark
AF
.
Tissue transglutaminase elevates intraocular pressure in mice
.
Invest Ophthalmol Vis Sci
.
2017
Dec
;
58
(
14
):
6197
211
.
[PubMed]
0146-0404
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.